Progenics Pharmaceuticals, Inc. (PGNX) related to its sale to Lantheus Holdings, Inc. Under the terms of the transaction, each share of Progenics common stock issued will automatically be converted into the right to receive 0.2502 of a share of Lantheus common stock for each share of Progenics common stock.